Amarendra Pegu

This paper uses humanized mice to study how HIV resistance to broadly neutralizing antibodies (bNAbs) affects the efficacy of AAV-delivered immunotherapy, finding that escape mutation fitness costs and resistance benefits determine therapeutic success.

This study identifies two broadly neutralizing sarbecovirus antibodies that resist viral evolution and show improved neutralization when combined.

This study shows that combining VRC01 and Rh-4β7 antibodies delays SHIV infection, preserves CD4+ T cells, and alters immune responses in macaques.